Why This Peptide Business Probably Won't Work

What's the plan?

Two tech founders want to start a company in the peptide drug world. Peptides are short chains of amino acids that some clinics prescribe for healing, energy, or anti-aging. The plan has three parts:

A subscription website — $10/month for regular people,$ 100/month for doctors. It would share peptide info and reviews.
Software for clinics — $999 to$ 3,500 per month for clinics that prescribe peptides. Plus $35 every time a prescription gets filled.
A direct-to-consumer brand — saved for later.

They plan to work with one compounding pharmacy run by a guy named Raja. They want to raise $5 million now and grow fast.

The bottom line: don't do this

After a deep look, this venture has too many serious problems. Here are the biggest ones.

Problem 1: The product they want to sell already exists for free

Big compounding pharmacies like Empower, Strive, Olympia, and Tailor Made already give clinics free software to order prescriptions. They make money from the drugs themselves, so the software is free as a way to keep clinics loyal.

This venture wants clinics to pay $999 to$ 3,500 a month for the same kind of tool. Why would clinics pay for what they already get for free?

Also, three other companies (Dr. Peptide, HolistiCare, and Ola Digital Health) are already building AI-powered peptide tools. So the "AI agent" idea isn't special either.

Problem 2: The founders may have read a key legal document backwards

There's a federal law called the Anti-Kickback Statute. It stops pharmacies from paying others for sending them prescriptions. The founders think they have a safe way around it, based on a government opinion called OIG 25-08.

Here's the problem: OIG 25-08 actually said this kind of fee structure is NOT okay. It's an unfavorable opinion, not a favorable one. The founders seem to be using the rejected example as their model. That's a serious legal risk.

Problem 3: A government meeting in July 2026 could destroy their supply

In July 2026, an FDA committee called PCAC will vote on whether seven specific peptides can keep being made by compounding pharmacies. The founders are betting these votes will go their way.

But the track record is brutal:

PCAC has rejected 9 out of 9 synthetic peptides they have ever voted on
FDA scientists have never recommended approving a peptide for compounding
PCAC almost always agrees with FDA scientists

The chance that 4 or more of the 7 peptides get approved is only around 10–12%. If most fail, the supply chain shrinks fast.

Problem 4: Only one supplier — and no real backup

Their whole supply depends on Raja's pharmacy, and they haven't even signed a final deal yet. If anything goes wrong — a warning letter, an inspection problem, a license issue — the business stops.

The other big peptide pharmacies that could be a backup are also their competitors (because those pharmacies have their own clinic software). So they probably won't help.

To grow to 300 clinics, they'd need a much bigger type of pharmacy (called 503B) that costs $10–25 million and takes 1.5 to 3 years to build.

Problem 5: The team is missing key people

Healthcare is heavily regulated. Successful healthcare-software startups almost always have a doctor or healthcare expert as a co-founder. This team has neither. They're two technical people without:

A medical doctor
A healthcare lawyer or compliance expert
Anyone with peptide industry experience

There are maybe 30 people in the country who really know peptide compliance, and most already work for the competing pharmacies. Hiring one will be very hard.

Problem 6: The numbers don't add up

The founders claim each clinic customer is worth 143 times what it costs to get them. That's almost impossible. Real healthcare software companies see numbers more like 10 to 20 times. They are off by 7 to 14 times.

Other shaky numbers:

They expect 15,000 paid sign-ups in year one — only about 27 paid newsletters in the entire world earn that much
They charge doctors ** $100/month**, but UpToDate (the gold standard) costs$ 42/month
They predict 60% time savings from their AI, but real studies show only 3–15%

Problem 7: Other companies tried this and failed

The plan looks a lot like several big failures:

Olive AI — raised money at $4 billion, then shut down. Same "AI for healthcare" pitch.
Truepill — pharmacy software company that nearly collapsed.
Done Health — founder convicted of crimes in November 2025 for a similar telehealth + prescription model.
Hims — settled with Novo Nordisk in March 2026, ending its compounded drug subscription model.

What would change the answer?

The founders would need to prove things like:

Get a favorable OIG opinion (not the rejected one they have now)
Sign real customers paying $3,500/month today (not just maybes)
Hire a doctor co-founder and a real compliance expert
Show that PCAC actually approves most of the peptides in July 2026
Find a real backup pharmacy that isn't a competitor

If they can do at least three of these in 90 days, the answer might change. But right now, too many things have to go right at the same time. The math says there's only about a 1 to 4 percent chance all the pieces hold together.

Final answer

Do not invest in current form. Too many parts of the plan rest on things that probably won't happen.